“肠道微生物组组成可预测晚期肝细胞癌患者对纳武利尤单抗的反应的未来前景”。
Future prospect of "Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients".
机构信息
Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Jinzhong 030600, Shanxi Province,
Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Jinzhong 030600, Shanxi Province, China.
出版信息
World J Gastroenterol. 2022 May 28;28(20):2248-2250. doi: 10.3748/wjg.v28.i20.2248.
Recently, we read the article "Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients" with interest, and it is preliminary suggested that gut microbiota is closely related to therapeutic effect of nivolumab. Based on the meaningful results of this article, several valuable research directions are proposed to enhance the therapeutic effect of immune checkpoint inhibitors on advanced hepatocellular carcinoma.
最近，我们饶有兴致地阅读了一篇题为“肠道微生物组组成可以预测纳武利尤单抗治疗晚期肝细胞癌患者的反应”的文章，初步表明肠道微生物群与纳武利尤单抗的治疗效果密切相关。基于这篇文章的有意义的结果，提出了几个有价值的研究方向，以增强免疫检查点抑制剂对晚期肝细胞癌的治疗效果。
Zotero 插件